Anodal tDCS over the motor cortex improves pain but not physical function in chronic chikungunya arthritis: Randomized controlled trial - 09/05/24
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | Anodal tDCS over M1 reduces pain in people with chronic CHIKV arthralgia. |
• | tDCS may provide functional benefits in chronic CHIKV arthralgia. |
• | tDCS is an easy to use and low-cost intervention that could be used for arthralgia. |
Abstract |
Background |
Chikungunya virus (CHIKV) is a globally prevalent pathogen, with outbreaks occurring in tropical regions. Chronic pain is the main symptom reported and is associated with decreased mobility and disability. Transcranial direct current stimulation (tDCS) is emerging as a new therapeutic tool for chronic arthralgia.
Objective |
To evaluate the effectiveness of 10 consecutive sessions of anodal tDCS on pain (primary outcome) in participants with chronic CHIKV arthralgia. Secondary outcomes included functional status, quality of life, and mood.
Methods |
In this randomized, double-blind, placebo-controlled trial, 30 participants with chronic CHIKV arthralgia were randomly assigned to receive either active (n = 15) or sham (n = 15) tDCS. The active group received 10 consecutive sessions of tDCS over M1 using the C3/Fp2 montage (2 mA for 20 min). Visual analog scale of pain (VAS), health assessment questionnaire (HAQ), short-form 36 health survey (SF-36), pain catastrophizing scale, Hamilton anxiety scale (HAS), timed up and go (TUG) test, lumbar dynamometry, 30-s arm curl and 2-min step test were assessed at baseline, day 10 and at 2 follow-up visits.
Results |
There was a significant interaction between group and time on pain (p = 0.03; effect size 95 % CI 0.9 (-1.67 to -0.16), with a significant time interaction (p = 0.0001). There was no interaction between time and group for the 2-minute step test (p = 0.18), but the groups differed significantly at day 10 (p = 0.01), first follow-up (p = 0.01) and second follow-up (p = 0.03). HAQ and SF-36 improved but not significantly. There was no significant improvement in mental health, and physical tests.
Conclusion |
tDCS appears to be a promising intervention for reducing pain in participants with chronic CHIKV arthralgia, although further research is needed to confirm these findings and explore potential long-term benefits.
Trial Registration |
Brazilian Registry of Clinical Trials (ReBEC): RBR-245rh7.
Le texte complet de cet article est disponible en PDF.Keywords : Neuromodulation, Chronic pain, Arbovirus, Infection to arbovirus
Abbreviations : Active-G, CHIKV, HAQ, HAS, M1, PCS, SF-36, Sham-G, tDCS, TUG, VAS
Plan
Vol 67 - N° 4
Article 101826- mai 2024 Retour au numéro
Article précédent
- Interactive boxing–cycling on frailty and activity limitations in frail and prefrail older adults: A randomized controlled trial
- Yi-Jia Lin, Wei-Chun Hsu, Kai Chen Wang, Wan-Yan Tseng, Ying-Yi Liao
- Late-stage rehabilitation after anterior cruciate ligament reconstruction: A multicentre randomised controlled trial (PReP)
- Daniel Niederer, Matthias Keller, Karl-Friedrich Schüttler, Christian Schoepp, Wolf Petersen, Raymond Best, Natalie Mengis, Julian Mehl, Matthias Krause, Sarah Jakob, Max Wießmeier, Lutz Vogt, Lucia Pinggera, Daniel Guenther, Andree Ellermann, Turgay Efe, David A. Groneberg, Michael Behringer, Thomas Stein
Bienvenue sur EM-consulte, la référence des professionnels de santé.